Amendments to the Claims

1. (Currently amended) A compound represented by the formula (I):

wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different,

R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A is an optionally substituted benzene, an optionally substituted oxazole, an optionally substituted benzothiophen, an optionally substituted benzothiophen, an optionally substituted benzothiophen, an optionally substituted indazole,

X1 is an oxygen atom or a sulfur atom,

 X^2 is a bond, an oxygen atom or $-S(O)_{n-}$, wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, $-S(O)_{m^-}$, $-C(=O)-N(R^3)$ - or $-N(R^3)-C(=O)$ - and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹, and M² and M³ may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, M³ is an optionally substituted divalent aliphatic hydrocarbon group and M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, <u>and (2)</u> when Y is a bond and one of M¹ and M² is a bond, the other of M¹ and M² is neither a bond nor methylene₅ and (3) 3-[3-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-5-phenyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-6-methyl]benzoyl]amino]-3-phenyl-

3-furanyl)carbonyl]amino]phenyl] 2-propenoic acid and 4-[[(2-methyl-5-phenyl 3-furanyl)carbonyl]amino]benzeneacetic acid are excluded.

2. (Original) The compound according to the claim 1, wherein R is an optionally substituted alkyl, an optionally substituted aralkyl, an optionally substituted cycloalkyl or an optionally substituted aryl.


- 3. (Original) The compound according to the claim 1, wherein p is 1.
- **4.** (Original) The compound according to the claim 1, wherein R^1 is a hydrogen atom.
- **5.** (Original) The compound according to the claim 1, wherein R² is an optionally substituted phenyl.

6-8. (Cancelled)

9. (Previously presented) The compound according to the claim 1, wherein the formula:



is the formula:



wherein Ring A' is an optionally further substituted benzene ring.

- 10. (Original) The compound according to the claim 1, wherein X^1 is an oxygen atom.
- 11. (Currently amended) The compound according to the claim 1, wherein X^2 is a bond, an oxygen atom or a sulfur atom.

- 12. (Original) The compound according to the claim 1, wherein Y is an oxygen atom or a sulfur atom.
- 13. (Previously presented) The compound according to the claim 1, wherein Y is -C(=0)- $N(R^3)$ -, wherein R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and the carbon atom is bonded to M^1 , and the nitrogen atom to M^2 .
- **14.** (Original) The compound according to the claim 13, wherein R³ is a hydrogen atom, an optionally substituted alkyl, an optionally substituted aralkyl, an optionally substituted cycloalkyl or an optionally substituted aryl.
- 15. (Original) The compound according to the claim 1, wherein M¹ is an alkylene having 3 or more carbon atoms.
- **16.** (Currently amended) The compound according to the claim 1, wherein M^1 and M^2 and M^3 may be the same or different and are each independently a bond, an alkylene, an alkenylene or an alkynylene, M^3 is an alkylene, an alkenylene or an alkynylene, and M^4 is an alkylene, an alkenylene or an alkynylene.

17. (Cancelled)

18. (Currently amended) The compound according to the claim 1, wherein the formula (I) is

$$R^{2} \xrightarrow{X^{1}}_{R} R^{2} \xrightarrow{M^{2}}_{A} X^{2} \xrightarrow{M^{4}}_{C} C_{R^{1}}$$
 (I')

wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R¹ is a hydrogen atom or an optionally substituted hydrocarbon group, R² is an optionally substituted aromatic group,

4

Ring A is an optionally substituted benzene, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted benzothiophen, an optionally substituted benzofuran or an optionally substituted indazole,

X1 is an oxygen atom or a sulfur atom,

 X^2 is a bond, an oxygen atom or $-S(O)_n$, wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, $-S(O)_{m^-}$, $-C(=O)-N(R^3)$ - or $-N(R^3)-C(=O)$ - and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹, and M² and M³ may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, M³ is an optionally substituted divalent aliphatic hydrocarbon group, and M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, <u>and (2)</u> when Y is a bond and one of M¹ and M² is a bond, the other of M¹ and M² is neither a bond nor methylene₅ and (3) 3 [3 [[(2 methyl-5-phenyl-3 furanyl)carbonyl]amino]phenyl] 2 propenoic acid, 4 [[(2-methyl-5-phenyl-3 furanyl)carbonyl]amino]benzeneacetic acid, 5 -[[4 -[(1Z) 2 carboxy-2-chloroethenyl]benzoyl]amino] 3 phenyl-2-thiophenecarboxylic acid, 3 -[3 -[[(2 methyl-5-phenyl-3 furanyl)carbonyl]amino]phenyl] 2 propenoic acid and 4 [[(2 methyl-5-phenyl-3 furanyl)carbonyl]amino]benzeneacetic acid are excluded.

19. (Currently amended) The compound according to the claim 18, wherein the formula (I') is

$$R^{2} \xrightarrow{M^{1}}_{R} Y \xrightarrow{M^{2}}_{R} A' \xrightarrow{M^{3}}_{X^{2}} \xrightarrow{M^{4}}_{Q} \bigcirc R^{1}$$

wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A' is an optionally further substituted benzene ring,

X¹ is an oxygen atom or a sulfur atom,

 X^2 is a bond, an oxygen atom or $-S(O)_n$, wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, $-S(O)_{m^-}$, $-C(=O)-N(R^3)$ - or $-N(R^3)-C(=O)$ - and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹, and M² and M³ may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, M³ is an optionally substituted divalent aliphatic hydrocarbon group, and M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, <u>and (2)</u> when Y is a bond and one of M¹ and M² is a bond, the other of M¹ and M² is neither a bond nor methylene, and (3) 3-[3-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino] 3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid are excluded.

- **20.** (Currently amended) The compound according to the claim 19, wherein X^1 is an oxygen atom, X^2 is an oxygen atom or $-S(O)_n$ -, wherein n is 0, 1 or 2, Y is an oxygen atom, M^1 is an optionally substituted C_{1-3} alkylene, M^2 is a bond, M^3 is a bond or an optionally substituted methylene, and M^4 is an optionally substituted methylene.
- **21.** (Original) The compound according to the claim 20, wherein M¹ and M³ may be the same or different and are each independently an optionally substituted methylene.

22-25. (Cancelled)

26. (Currently amended) The compound according to the claim 18, wherein the formula (I') is

wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A' is an optionally further substituted benzene ring,

X1 is an oxygen atom or a sulfur atom,

 X^2 is a bond, an oxygen atom or $-S(O)_n$, wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, $-S(O)_{m^-}$, $-C(=O)-N(R^3)$ - or $-N(R^3)-C(=O)$ - and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹ is an alkylene group having 3 or more carbon atoms,

M³ is a bond or an optionally substituted divalent aliphatic hydrocarbon group, and

M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or $-S(O)_{m^-}$, $M^{1'}$ is not a bond, <u>and (2)</u> when Y is a bond $M^{1'}$ is neither a bond nor methylene, and (3) 3 [3-[[(2-methyl-5-phenyl-3-

furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[[(2-methyl-5-phenyl-3-

furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-

chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[[(2-methyl-5-phenyl-3-

furanyl)carbonyl]amino]benzeneacetic acid are excluded.

27. (Currently amended) The compound according to the claim 1, wherein R is an optionally substituted alkyl, aryl or cycloalkyl group, p is 0 or 1, R¹ is a hydrogen atom, R² is an optionally substituted phenyl group, Ring A is an optionally substituted benzene ring-or an optionally

substituted thiazole ring, X^1 is an oxygen atom, X^2 is a bond or an oxygen atom, Y is an oxygen atom or $-C(=O)-N(R^3)$ -, wherein R^3 is a hydrogen atom, alkyl or aralkyl, and the carbon atom is bonded to M^1 , and the nitrogen atom to M^2 , M^1 , and M^2 and M^3 may be the same or different and are each independently a bond or alkylene, M^3 is alkylene, and M^4 is alkylene.

- 28. (Currently amended) The compound according to the claim 1, wherein R is an optionally substituted alkyl, aryl or cycloalkyl group, p is 0 or 1, R^1 is a hydrogen atom, R^2 is an optionally substituted phenyl group, Ring A is an optionally substituted benzene ring-or an optionally substituted thiazole ring, X^1 is an oxygen atom, X^2 is a bond or $-S(O)_n$, wherein n is 0, 1 or 2, Y is an oxygen atom or $-C(=O)-N(R^3)$, wherein R^3 is a hydrogen atom, alkyl or aralkyl, and the carbon atom is bonded to M^1 , and the nitrogen atom to M^2 , M^1 , and M^2 and M^3 may be the same or different and are each independently a bond or alkylene, M^3 is alkylene, and M^4 is alkylene.
- **29.** (Original) A prodrug of the compound according to the claim 1.
- **30.** (Previously presented) A pharmaceutical medicine composition comprising the compound according to the claim 1 or a prodrug thereof and a pharmaceutically acceptable carrier, excipient or diluent.
- 31. (Original) An agent of regulating nuclear receptor PPAR comprising the compound according to the claim 1 or a prodrug thereof.

32. (Cancelled)

- **33.** (Previously presented) The agent according to the claim 31, which is a therapeutic agent forlipid metabolism abnormality or sequelae thereof, arteriosclerotic disease or sequelae thereof, diabetes mellitus, or impaired glucose tolerance.
- **34.** (Original) The medicine according to the claim 30, which is an agent of raising high-density lipoprotein cholesterol, an agent of lowering triglyceride, an agent of lowering low-density lipoprotein cholesterol or an agent of suppressing progress of arteriosclerotic plaque.

- **35.** (Original) An agent of regulating GPR40 receptor function comprising the compound according to the claim 1 or a prodrug thereof.
- 36. (Original) The agent according to the claim 35, which is an agent of regulating insulin secretion, an agent of lowering blood glucose or an agent of protecting pancreatic β cell.
- **37.** (**Previously presented**) The agent according to the claim 35, which is a therapeutic agent for diabetes mellitus, glucose intolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, hyperlipidemia, arteriosclerosis, obesity, hypoglycaemia, insulin resistant syndrome, unstable diabetes mellitus, or insulin allergy.

38-51. (Cancelled)